40592-V08H Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Sino Biological sars cov 2 2019 ncov spike rbd his recombinant protein covid 19 spike rbd research
    Sars Cov 2 2019 Ncov Spike Rbd His Recombinant Protein Covid 19 Spike Rbd Research, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2 2019 ncov spike rbd his recombinant protein covid 19 spike rbd research/product/Sino Biological
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 2019 ncov spike rbd his recombinant protein covid 19 spike rbd research - by Bioz Stars, 2021-04
    94/100 stars
      Buy from Supplier

    97
    Sino Biological sars cov 2 rbd
    Correlations of <t>SARS-CoV-2</t> NAb titers (a), pseudovirus titers (b), and RBD protein specific IgG titers (c) prior to challenge with log peak mRNA copies/g in lungs following challenge in hACE2-Tg mice. Red lines reflect the best-fit relationship between these variables. P and R values reflect two-sided Spearman rank-correlation tests.
    Sars Cov 2 Rbd, supplied by Sino Biological, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2 rbd/product/Sino Biological
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 rbd - by Bioz Stars, 2021-04
    97/100 stars
      Buy from Supplier

    97
    Sino Biological 40592 v08h
    Correlations of <t>SARS-CoV-2</t> NAb titers (a), pseudovirus titers (b), and RBD protein specific IgG titers (c) prior to challenge with log peak mRNA copies/g in lungs following challenge in hACE2-Tg mice. Red lines reflect the best-fit relationship between these variables. P and R values reflect two-sided Spearman rank-correlation tests.
    40592 V08h, supplied by Sino Biological, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/40592 v08h/product/Sino Biological
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    40592 v08h - by Bioz Stars, 2021-04
    97/100 stars
      Buy from Supplier

    Image Search Results


    Correlations of SARS-CoV-2 NAb titers (a), pseudovirus titers (b), and RBD protein specific IgG titers (c) prior to challenge with log peak mRNA copies/g in lungs following challenge in hACE2-Tg mice. Red lines reflect the best-fit relationship between these variables. P and R values reflect two-sided Spearman rank-correlation tests.

    Journal: bioRxiv

    Article Title: Recombinant Fc-fusion vaccine of RBD induced protection against SARS-CoV-2 in non-human primate and mice

    doi: 10.1101/2020.11.29.402339

    Figure Lengend Snippet: Correlations of SARS-CoV-2 NAb titers (a), pseudovirus titers (b), and RBD protein specific IgG titers (c) prior to challenge with log peak mRNA copies/g in lungs following challenge in hACE2-Tg mice. Red lines reflect the best-fit relationship between these variables. P and R values reflect two-sided Spearman rank-correlation tests.

    Article Snippet: The cell culture supernatants were collected and analyzed by western blot analysis using a commercial antibody (Sino Biological Inc. Beijing, China) against SARS-CoV-2 RBD.

    Techniques: Mouse Assay

    SARS-Cov2 RBD-Fc Vacc elicit strong humoral immunity in macaca fascicularis. a) Schematic diagram of immunization, sample collection and challenge schedule. b). Macaca fascicularis (n=5) were immunized on day 0, day 14, d28 with 20ug and 40ug doses of RBD-Fc Vacc or PBS and the serum were collected at the indicated time. The SARS-CoV-2 RBD specific IgG were examined by ELISA. c) Neutralizing antibodies were determined by microneutralization assay using the SARS-CoV-2 (NT50). d). Correlation analysis of antibody titers tested by ELISA and microneutralization assay. P and R values reflect two-sided Spearman rank-correlation tests. e) Serum cross neutralization against SARS-CoV-2 epidemic strains in RBD-Fc immunized macaca fascicularis. NT50 against the SARS-CoV-2 epidemic strains (BJ08, BJ05, BJ01) were performed using macaca fascicularis sera collected at 21 days post third immunization. Data are analyzed by one-way ANOVA with multiple comparison tests. (n.s., not significant).

    Journal: bioRxiv

    Article Title: Recombinant Fc-fusion vaccine of RBD induced protection against SARS-CoV-2 in non-human primate and mice

    doi: 10.1101/2020.11.29.402339

    Figure Lengend Snippet: SARS-Cov2 RBD-Fc Vacc elicit strong humoral immunity in macaca fascicularis. a) Schematic diagram of immunization, sample collection and challenge schedule. b). Macaca fascicularis (n=5) were immunized on day 0, day 14, d28 with 20ug and 40ug doses of RBD-Fc Vacc or PBS and the serum were collected at the indicated time. The SARS-CoV-2 RBD specific IgG were examined by ELISA. c) Neutralizing antibodies were determined by microneutralization assay using the SARS-CoV-2 (NT50). d). Correlation analysis of antibody titers tested by ELISA and microneutralization assay. P and R values reflect two-sided Spearman rank-correlation tests. e) Serum cross neutralization against SARS-CoV-2 epidemic strains in RBD-Fc immunized macaca fascicularis. NT50 against the SARS-CoV-2 epidemic strains (BJ08, BJ05, BJ01) were performed using macaca fascicularis sera collected at 21 days post third immunization. Data are analyzed by one-way ANOVA with multiple comparison tests. (n.s., not significant).

    Article Snippet: The cell culture supernatants were collected and analyzed by western blot analysis using a commercial antibody (Sino Biological Inc. Beijing, China) against SARS-CoV-2 RBD.

    Techniques: Enzyme-linked Immunosorbent Assay, Microneutralization Assay, Neutralization

    Characterization of the cellular immune response for SARS-CoV-2 RBD-Fc vaccine. a) ELISPOT assay for IFN-γ in PBMCs from macaca fascicularis. Data are shown as mean ± SEM. Significance was calculated using unpaired t-test (n.s., not significant). b). SARS-CoV-2 RBD-specific IL-4 + T cells and TNF-a + T cells in CD4 + T and CD8 + T cells from macaca fascicularis PBMCs were detected by flow cytometry.

    Journal: bioRxiv

    Article Title: Recombinant Fc-fusion vaccine of RBD induced protection against SARS-CoV-2 in non-human primate and mice

    doi: 10.1101/2020.11.29.402339

    Figure Lengend Snippet: Characterization of the cellular immune response for SARS-CoV-2 RBD-Fc vaccine. a) ELISPOT assay for IFN-γ in PBMCs from macaca fascicularis. Data are shown as mean ± SEM. Significance was calculated using unpaired t-test (n.s., not significant). b). SARS-CoV-2 RBD-specific IL-4 + T cells and TNF-a + T cells in CD4 + T and CD8 + T cells from macaca fascicularis PBMCs were detected by flow cytometry.

    Article Snippet: The cell culture supernatants were collected and analyzed by western blot analysis using a commercial antibody (Sino Biological Inc. Beijing, China) against SARS-CoV-2 RBD.

    Techniques: Enzyme-linked Immunospot, Flow Cytometry

    SARS-Cov2 RBD-Fc vaccine Design. a) Two RBD domains are fused through Fc fragment to form the Y-shaped structure via protein structure prediction server version 3.0 (left panel). RBD-Fc protein expressed from CHO cells were identified by western blot under reduced and non-reduced condition using both anti-serum from COVID-19 recovered patients and commercial antibody (right panel). b) N-glycosylation and O-glycosylation sites identified using mass spectrum (up panel). The docking between ACE-2 and RBD-Fc predicted by ZDOCK server. An overview of the glycosylation sites illustrated based on the solved complex structure of SARS-CoV-2 RBD-Fc bound to ACE2 (PDB code: 1R42). The identified sites, colored red for N-glycosylation, purple for O-glycosylation are shown as spheres and labeled. The right panel (surface representation) was generated by rotating the structure in the Left panel (cartoon representation) around a vertical axis for about 90° (lower panel). c) The real-time binding profile between our purified RBD-Fc protein and ACE2 characterized by SPR Biacore. d e) Balb/C mice were immunized with RBD-his or RBD-Fc (10ug/mouse) in the presence of aluminum at d0 and d14. Two weeks post last vaccination the serum were collected ELISA assay shows the SARS-CoV-2 RBD-specific IgG titers (d). SARS-CoV-2 neutralization assay shows the NT50 (e).

    Journal: bioRxiv

    Article Title: Recombinant Fc-fusion vaccine of RBD induced protection against SARS-CoV-2 in non-human primate and mice

    doi: 10.1101/2020.11.29.402339

    Figure Lengend Snippet: SARS-Cov2 RBD-Fc vaccine Design. a) Two RBD domains are fused through Fc fragment to form the Y-shaped structure via protein structure prediction server version 3.0 (left panel). RBD-Fc protein expressed from CHO cells were identified by western blot under reduced and non-reduced condition using both anti-serum from COVID-19 recovered patients and commercial antibody (right panel). b) N-glycosylation and O-glycosylation sites identified using mass spectrum (up panel). The docking between ACE-2 and RBD-Fc predicted by ZDOCK server. An overview of the glycosylation sites illustrated based on the solved complex structure of SARS-CoV-2 RBD-Fc bound to ACE2 (PDB code: 1R42). The identified sites, colored red for N-glycosylation, purple for O-glycosylation are shown as spheres and labeled. The right panel (surface representation) was generated by rotating the structure in the Left panel (cartoon representation) around a vertical axis for about 90° (lower panel). c) The real-time binding profile between our purified RBD-Fc protein and ACE2 characterized by SPR Biacore. d e) Balb/C mice were immunized with RBD-his or RBD-Fc (10ug/mouse) in the presence of aluminum at d0 and d14. Two weeks post last vaccination the serum were collected ELISA assay shows the SARS-CoV-2 RBD-specific IgG titers (d). SARS-CoV-2 neutralization assay shows the NT50 (e).

    Article Snippet: The cell culture supernatants were collected and analyzed by western blot analysis using a commercial antibody (Sino Biological Inc. Beijing, China) against SARS-CoV-2 RBD.

    Techniques: Western Blot, Labeling, Generated, Binding Assay, Purification, SPR Assay, Mouse Assay, Enzyme-linked Immunosorbent Assay, Neutralization

    Principal findings and conceptual model. ( A ) ACE2-Fc binding was measured to wild-type or glycoEnzyme-KO 293 T cells expressing Spike. Sialidase treatment of cells was performed in some cases. Similar studies also measured S1-Fc and RBD-Fc binding to cell-surface expressed ACE2. ( B ) SARS-CoV-2 pseudovirus (bearing Spike-WT, Spike-mut, Spike-delta variants) were generated in wild-type or glycoEnzyme-KO 293Ts, in the presence and absence of kifunensine. Main results of binding ( A ) and viral entry ( B ) assay are listed. ( C ) Conceptual model shows that kifunensine can induce S1-S2 site proteolysis on Spike-WT and Spike-mut virus, but not Spike-delta virus. This proteolysis reduces RBD presentation and attenuates viral entry into 293T/ACE2. Without affecting S1-S2 cleavage, kifunensine also partially reduced Spike-delta pseudovirus entry function. The data suggest additional roles for Spike N-glycans during viral entry.

    Journal: eLife

    Article Title: Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration

    doi: 10.7554/eLife.61552

    Figure Lengend Snippet: Principal findings and conceptual model. ( A ) ACE2-Fc binding was measured to wild-type or glycoEnzyme-KO 293 T cells expressing Spike. Sialidase treatment of cells was performed in some cases. Similar studies also measured S1-Fc and RBD-Fc binding to cell-surface expressed ACE2. ( B ) SARS-CoV-2 pseudovirus (bearing Spike-WT, Spike-mut, Spike-delta variants) were generated in wild-type or glycoEnzyme-KO 293Ts, in the presence and absence of kifunensine. Main results of binding ( A ) and viral entry ( B ) assay are listed. ( C ) Conceptual model shows that kifunensine can induce S1-S2 site proteolysis on Spike-WT and Spike-mut virus, but not Spike-delta virus. This proteolysis reduces RBD presentation and attenuates viral entry into 293T/ACE2. Without affecting S1-S2 cleavage, kifunensine also partially reduced Spike-delta pseudovirus entry function. The data suggest additional roles for Spike N-glycans during viral entry.

    Article Snippet: These studies used Alexa-647 conjugated anti-ACE2 (MAB9332, R and D systems) and anti-RBD (Sino Biologicals) antibodies.

    Techniques: Binding Assay, Expressing, Generated